How This Works
KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols.
Potential Benefits & Side Effects
Observations from preclinical and early‑stage research.
Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation.
Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability.
Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation.
Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
No melanotropic effects: Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation.
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.